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Summary We have examined the incidence of Harvey ras mutations in human squamous cell carcinomas
(SCC) of the upper aerodigestive tract using the polymerase chain reaction (PCR) followed by direct
sequencing. No mutations were detected at codons 12, 13, 59 or 61 of this gene in any of six papillomas, five
erythroplakias, 56 squamous cell carcinomas, and 16 SCC cell lines. Some of the SCC were lymph node
metastases (three) or tumours which had recurred following radiotherapy (seven). We conclude that Harvey
ras mutations are not a common event in the pathogenesis or recurrence of SCCs from Caucasian subjects, in
contrast to the situation with Indian populations (Saranath et al., 1991).
Ras mutations have been detected in a wide range of human
tumours (Bos et al., 1989), and in the case of N-ras can be
demonstrated to be important to the transformed phenotype
(Paterson et al., 1987). Several studies have shown that the
incidence of Harvey ras (H-ras) mutations in squamous cell
carcinoma (SCC) of the head and neck (H & N) in Western
Europe is low, but the role of ras mutations in the progres-
sion and development of SCC of the H & N is still unclear.
H-ras point mutations were found by Saranath et al. (1991)
in 35% of squamous cell carcinomas of the oral cavity in
India and most of these patients chew tobacco which is a
well described risk factor (Sankaranarayanan, 1990). Two ras
mutations were found by Rumsby et al. (1990) looking at 37
SCCs of the H & N. However half of these patients and all
their cell lines were treated with radiotherapy prior to
analysis. Thus half of these were late-stage tumours or recur-
rent tumours by definition; the staging for the others was not
given but is likely to be late-stage. Sheng et al. (1990) also
found a low incidence of H-ras mutations in SCCs of the
H&N (2 of 54). All their patients were untreated but only
nine were possibly early stage and data was again not shown
for the staging. More recently, Chang et al. (1991) reported
the absence of ras mutations in 22 SCC biopsies from the H
& N. In a study of human epidermal neoplasms however,
30% of a large series of benign epidermal keratoacanthomas
were reported to contain ras mutations in contrast to only
13% of malignant SCC (Corominas et al., 1989). Similarly,
in animal epidermal tumour models ras mutations were also
shown to be more prevalent in benign lesions than malignant
lesions (Balmain et al., 1984; Leon et al., 1988; Corominas et
al., 1991; Brown et al., 1990). We therefore thought it possi-
ble that ras mutations are important for the initiation of
SCC of the H and N but are eliminated at an early stage of
progression.
The presence of a ras mutation in a human keratinocyte
can render the cells more responsive to epidermal growth
factor (Henrard et al., 1990) and can clearly give these cells a
selective advantage in vivo (Corominas et al., 1989; Saranath
et al., 1991). However, it has been suggested that in most
circumstances, the presence of a ras mutation selects against
further progression to SCC, due to its inability to amplify
signals associated with terminal differentiation as well as
proliferation (Corominas et al., 1989). Whilst this may be
true, it is also likely that ras mutations lead to the secretion
of transforming growth factor a (TGF-a) by the keratino-
cytes which possess them (Ozanne et al., 1980). These cells
might then contribute to the clonal expansion of other malig-
nant cells which have a greater potential to progress than
those actually carrying the ras, mutation. Indeed, benign
mouse epidermal papillomas which are known to be poly-
clonal (Winton et al., 1989) do express high levels of TGF-a
(Glick et al., 1991).
We were therefore concerned that an important function of
ras mutations might have been missed because too few
premalignant or early stage carcinoma lesions had been
examined. We have extended the work of previous inves-
tigators and screened a number of lesions and cell lines at all
stages of SCC development for H-ras mutations, using PCR
followed by direct single-stranded sequencing. This allows the
detection of all the known activating mutations of the H-ras
gene (see Gibbs et al., 1985 for a review).
We have obtained results however, which show for the first
time that H-ras mutations are also scarce in the early stages
of H & N SCC development in Caucasian patients. These
results are discussed in relation to the pathogenesis of SCC in
Caucasian and Indian patients.
Materials and methods
Tumour samples
Twenty-six SCCs, five erythroplakias and six recurrent res-
piratory papillomas have been collected and snap frozen
from Glasgow and Edinburgh. In addition 30 archival SCC
embedded in paraffin blocks were obtained from Aberdeen.
All the SCC were placed into the appropriate TNM tumour
staging group (UICC 1987). Frozen and paraffin sections
(5,lm thickness) were prepared by Ian McMillan (Depart-
ment of Veterinary Pathology, University of Glasgow).
Cell lines and cell culture
The SCC cell lines have been described previously (Rhein-
wald & Beckett, 1981). The new B.I.C.R. cell lines (BICR 3,
6, 7, 10, 16, 18, 19, 22, 31 and 56) were derived following
explant culture of tumour fragments in DMEM plus 10% v/v
FBS, 0.4Agml-' hydrocortisone and lethally irradiated 3T3
cells (Edington et al. - manuscript in preparation). The cells
have now completed more than 100 population doublings
and are considered to be established. The cells were grown
initially on irradiated 3T3 feeder layers as originally des-
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cribed by Rheinwald and Beckett (1981) in Dulbecco's
modification of Eagles Medium (DMEM), 10% (v/v) foetal
bovine serum and 0.4yg-g hydrocortisone. Forty eight hours
before the DNA was isolated the medium was changed to
MCDB 153 medium containing low concentrations
(O.15 mmol ') of calcium ions, 0.4% v/v bovine pituitary
extract, 5ILgml-' epidermal growth factor, 0.5,pgml-' hyd-
rocortisone and antibiotics (all from Clonectics Inc., San
Diego USA). The low calcium medium facilitated the
removal of the Swiss 3T3 feeder layer with 0.02% EDTA as
described by Rheinwald and Green (1975) and ensured
minimal (less than 1%) contamination of the cultures with
mouse DNA (see also Parkinson & Newbold 1980; Alitalo et
al., 1982). Normal human keratinocytes were used as a nor-
mal tissue control and were grown throughout on MCDB153
medium plus additives (see above). The human bladder car-
cinoma line EJ which is known to harbour a G-> T
mutation at the second base of codon 12 of the H-ras gene
(Tabin et al., 1982) was used as a mutant control during the
development of the direct sequencing techniques and was
cultured in Special Liquid Medium (Life Sciences Tech-
nology, Paisley, Scotland) containing 10% v/v foetal bovine
serum.
The erythroplakia keratinocytes were cultured in DMEM,
20% vol./vol. foetal bovine serum, 0.4jigml1' hydrocor-
tisone, 10 ng ml-' cholera toxin (Sigma Chemical Co., Poole,
UK) and will be described in detail elsewhere (Edington et al.
- manuscript in preparation). Briefly, the erythroplakia cells
are diploid but appear to differentiate less than normal
keratinocytes as assessed by involucrin staining, electron mic-
roscopy and response to suspension culture. The cells do
eventually senesce however, have normal keratinocyte growth
requirements, and are not tumorigenic in nude mice. These
properties are consistent with an abnormal premalignant
population of human cells (see Paraskeva et al., 1984). The
cells also have ultrastructural and immunocytochemical
features of keratinocytes.
DNA extraction
DNA extraction was by a simplification of the method des-
cribed by Gross-Bellard et al. (1973). Each 5tim frozen
section was lysed in 100,ul DNA lysis buffer (10 mmol 1-1 Tris-
HCI, 10 mmol 1-' EDTA, 10 mmol 1-' NaCl) pH 8.0 plus 29jil
20% sarcosine, 20ILI of 20 mg ml 1' Proteinase K at 37°C
overnight. The preparation was then extracted with 100 lal of
phenol/chloroform and the supernatant precipitated with
10 O,l of 3 M sodium acetate and 300,ul of 100% ethanol at
- 20°C overnight. The precipitates were then pelleted by
centrifuging (14,000g) for 30 min, washed in 80% ethanol,
pelleted again by centrifuging at 8,500g for 15 min, dried
and resuspended in 100 ILI of Tris-EDTA (10 mmol l-' Tris-
HCI, 1 mmol l- 1 EDTA) pH 8.0. The cell cultures were
treated as above except that DNA was spooled by the
method of Gross-Bellard et al. (1973) rather than being
pelleted.
The paraffin-embedded sections were extracted twice with
1 ml xylene for 30 min with gentle tumbling followed each
time with a 5 min spin at 14,000g (Dubeau et al., 1986).
After the second extraction the tissues were rinsed with
500 ILI of 100% ethanol and lysed in the same fashion as the
frozen sections.
HEK
PCR and direct single-stranded sequencing
PCR primers were (reading 5' to 3')
H ras codons 12, 13 a primer: AGG AGA CCC TGT
AGG AGG AC
d primer: AGC AGC TGC TGG
CAC CTG GA
H ras codons 59-63 a' primer: CAG GAT TCC TAC
CGG AAG CA
c' primer: CTG TAC TGG TGG
ATG ATG TCC TCAA
Sequencing Primers were (reading 5' to 3')
H ras codons 12, 13 b primer: AGG CCC CTG AGG
AGC GAT GA
c primer: GGA TCA GCT GGA
TGG TCA GC
H ras codons 59-63 8 primer: CGC ATG TAC TGG
TCC CGC AT
b' primer: GAC GTG CCT GTT
GGA CAT CC
The primers were synthesised on a standard Applied
Biosystems machine with an elongated coupling time for the
biotinylated group which is added at the 5' end as the last
step. The primers were purified using a desalting protocol
with an oligonucleotide purification cartridge (Applied
Biosystems, UK).
The PCR products were purified using magnetic strep-
tavidin coated beads - Dynabeads M-280 Streptavidin
(Dynal, UK Ltd.) and a magnetic separator MPC-E (Dynal,
UK Ltd.). This enabled direct solid-phase sequencing of the
PCR products to be undertaken (Hultman et al., 1991) and
mutations or polymorphisms could be detected not only
across the codons of interest but up to 200 base pairs away.
Results
Sensitivity ofthe PCR/direct sequencing technique
PCR and direct sequencing were chosen as the methods for
investigating the possibility of ras mutations because dot-
blotting for point mutations is not as informative as direct
sequencing. All the regions of interest (codons 12 and 13 or
codons 59-63) are seen with direct sequencing in addition to
flanking sequences. Also it is not possible to obtain human
cells and tissues carrying activating point mutations at
codons 59 or 63 and it is arguable whether synthetic
oligonucleotides represent an adequate control.
Many tumour biopsies are contaminated by normal cells.
Therefore, to determine the sensitivity of the direct sequenc-
ing technique samples of EJ bladder carcinoma DNA were
mixed at different ratios with normal human keratinocyte
DNA, before subjecting the samples to PCR and analysis by
direct sequencing. Figure 1 shows that the codon 12 ras
mutation harboured by the EJ line is still easily detectable
even when the mutant DNA represented only 15% of the
sample. Examination of stained sections of all the tumour
samples by a trained pathologist revealed that tumour tissue
represented at least 45% of the cells in the section and
therefore that a mutation would be detected in these
cases.
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Figure 1 Sensitivity of PCR and direct sequencing in the detection of mutant Harvey ras genes. Normal HEK DNA (GGC) was
mixed in different ratios with EJ Bladder carcinoma DNA (GTC) to determine the sensitivity of mutant ras detection. The T lane
was clearly visible when the EJ DNA represented only 15% of the total DNA.HARVEY RAS MUTATIONS IN SCC 619
Table I Benign premalignant and malignant head and neck lesions analysed
Lesion Tested Cultures Treatment prior to surgery
Benign papillomas 6 2 6 CO2 Laser therapy
Premalignant erythroplakias 5 4 None
Malignant SCC TI 4 0 None
T2 16 1 + 2a 2 DXT
T3 12 0 1 DXT
T4 24 4 1 DXT, Caesium implant
Spindle Carcinoma 2 0 2 DXT
Lymph node metastases 3 2 None
Cell lines
SCC-4 DXT, Methotrexate
SCC-9 None
SCC-12 Clone B None
SCC-12 Clone F None
SCC-13 DXT
SCC-15 None
SCC-25 None
aDXT = Deep X-ray Therapy.
Absence ofH-ras mutations at all stages ofhead and neck
SCC development
Table I summarises all the benign, premalignant and SCC
biopsies tested for H-ras mutations, and in some cases the
keratinocytes cultured from them. No ras mutations were
present in six benign papillomas, five premalignant erythrop-
lakias, 4 T1, 16 T2, 12 T3 and 24 T4 and two spindle cell
malignant SCC, all but five of which were untreated. Also,
no mutations were detected in three SCC lymph node metas-
tases. In addition cultures of four erythroplakia biopsies and
16 SCC cell lines all possessed normal H-ras genes.
Discussion
We have confirmed and extended the observations of
previous investigators (Rumsby et al., 1990; Sheng et al.,
1990; Chang et al., 1991) to demonstrate that mutations in
the H-ras proto-oncogene are extremely rare in the
pathogenesis of H & N SCC in Caucasian patients. Exten-
ding the findings of others, we were unable to find H-ras
mutations in 11 premalignant or benign lesions and 20 early
stage (T1, T2) untreated SCC which were not studied by the
earlier investigators. Similar findings were also reported
recently by Yeudall et al. (1993) who could not detect ras
mutations in any dysplastic oral biopsies from three patients.
Taken together these results do not support the hypothesis
that H-ras mutations are present during the early stages of H
& N SCC development and are later selected against during
tumour progression (see Introduction). The amount of
tumour present in each biopsy should have been enough to
render a mutation readily detectable by direct sequencing (see
Figure 1). Also in several cases cultures of epithelial cells
from the tumours or established tumorigenic cell lines were
studied (Table I) and these were unlikely to be contaminated
with normal cells. It is unlikely therefore that any mutations
in the H-ras gene would have been missed because of exces-
sive normal cell contamination.
The absence of H-ras mutations in Western samples of H
& N SCC contrasts with the findings of Saranath et al.
(1991) who reported finding H-ras mutations in 35% of
Indian SCC samples collected from patients who had
habitually chewed betal quid. These results do suggest
therefore that ras mutations can give keratinocytes a selective
advantage in H & N SCC sites and that they do persist
throughout tumour progression (see also Corominas et al.,
1989). It is also known that ras oncogenes can render human
keratinocytes more sensitive to EGF in vitro and when
grafted onto nude mice can regenerate an epithelium reminis-
cent of premalignant oral leukoplakia (Henrard et al., 1990).
Interestingly, tobacco-related oral malignancies in India are
usually preceded by premalignant lesions such as leukoplakia
(Daftary, 1990) whereas oral malignancies in Western count-
ries only rarely arise from premalignant lesions (Binnie,
1990).
It has been suggested that the absence of ras mutations in
Western samples could be due to the different types of
tobacco used in India and the UK (Chang et al., 1991) but
since most UK H & N SCC are thought to have a tobacco
smoking-related aetiology (Stell, 1972), and tobacco smoke
contains several carcinogens which are known to activate the
H-ras gene (IARC, 1986; Quintanilla et al., 1986; Brown et
al., 1990), this does not seem a satisfactory explanation.
Whilst it has still to be demonstrated that ras mutations are
an early event in the pathogenesis of Indian SCCs (Saranath
et al., 1991), it is possible that the betal quid contains tumour
promoters which give the ras mutations a continuous selec-
tive advantage, analagous to the mouse two-stage epidermal
tumorigenesis model (see Clark, 1993 for a review). It is
known that the quid is held for long periods of time at the
site of tumour induction (Chang et al., 1991; Saranath et al.,
1991), and continuous exposure to tumour promoters is
essential for their action (Boutwell, 1964).
It is clear that keratinocytes harbouring ras mutations can
gain a continuous selective advantage during the patho-
genesis of oral SCC, if the correct conditions for such selec-
tion prevail (Saranath et al., 1991). The exact nature of these
conditions remains to be established but an answer should
emerge when the molecular mechanisms of oral SCC induc-
tion in Caucasian and Indian subjects are understood in
more detail.
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